Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
Minnema
M C
MC
van der Veer
M S
MS
Aarts
T
T
Emmelot
M
M
Mutis
T
T
Lokhorst
H M
HM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis; D006086:Graft vs Host Disease / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D016879:Salvage Therapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide